Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076)
Debra L. Richardson, Erika Hamilton, Minal Barve, Charles Anderson, Sara Taylor, Nehal J. Lakhani, Joseph Buscema, Anthony W. Tolcher, Corrine Zarwan, Theresa L. Werner, John L. Hays, Rebecca C. Arend, Jeffery Edenfield, Emily Putiri, Patricia Bernardo, Robert A. Burger, Ursula A. Matulonis
Topics & Concepts
MedicineOvarian cancerInternal medicineBevacizumabFallopian tube cancerFallopian tubeOncologyGastroenterologyPhases of clinical researchChemotherapyUrologyCancerSurgeryOvarian cancer diagnosis and treatmentLung Cancer Treatments and MutationsRenal cell carcinoma treatment